The following article was provided to Human Paratuberculosis Foundation by Dr. Judith Lipton. It was written in May 2015, but still remains relevant today. It is an excellent overview of MAP, and provides practical advice for patients who want to convince their doctor to treat their MAP infection. HPF is grateful to Dr. Lipton for her contributions to the field and for providing this helpful article.
UPDATE: On March 24-25, 2017, MAP researchers and doctors from around the world will gather in Philadelphia, PA to share presentations and discuss how best to advance MAP science. Read the latest update about the Goals of the meeting, Discussion Topics, and Presenters list. Additionally, the latest sponsorship details are announced.
There are at least two ways that bacteria may play a role in inflammatory bowel disease. The top of the Hit Parade at present is the gut microbiome. Researchers, by using complex new technologies, can take a virtual snapshot of the bacterial DNA in the gut of the IBD patient (and in the normal patient, of course). Successful snapshots end up as publications if they demonstrate a difference in the gut microbiome between these two groups. If the IBD patient shows an abundance of a particular organism when it is not apparent in the control group, then this may indicate the presence of an organism capable of triggering an inflammatory reaction in the gut of the patient.
New Zealand is a collection of three islands. Life on an island is sustained by a complex infrastructure. Interdependence is the glue that results in sustainability. Sustainability, in turn, is ensured if the needs of both the population and the environment are addressed and met. The goal is harmony. Socially, islands resemble huge organisms; isolated yet functioning in a collective synchronicity with each of their parts. The organic model is not new – a group of organisms working together to the benefit of society. Ants build anthills, bees build beehives, people build complex societies.
Human Paratuberculosis Foundation would like to sponsor innovative human MAP trials in the future. Some research groups have begun trialing therapies that treat human MAP in Crohn’s disease. As the research progresses, HPF will provide information on newly initiated human MAP trials and give updates on the current trial results. Read more about trials which seek to treat human MAP in Crohn’s disease.
The Crohn’s Infection is proud to announce the formation of our new non-profit organization: Human Paratuberculosis Foundation. Human Paratuberculosis Foundation, Inc. is a non-profit organization founded in 2016 under the laws of the State of New York. We are an approved IRS 503(c)(1) charity. In addition, we are happy to let our community know about the 2017 MAP Conference to be held in Philadelphia on March 24-25th. Keep reading for more details and an opportunity to help!
Human Paratuberculosis Foundation is dedicated to providing the most up-to-date information in our field to assist patients around the world in making informed decisions about their treatment. We are grateful for the support of this community and look forward to taking this journey together.
Read all the latest news and research about Mycobacterium avium subsp. paratuberculosis (MAP) and the treatment of Crohn’s and other diseases using AMAT therapy. Enjoy!
by John Aitken and Kevin Taylor
The following abstract accompanied an oral presentation at a New Zealand veterinary conference in 2014, and it was a fair summary of our thinking at the time. Most of the problems outlined in the article have since been addressed by us. In addition, the contributing group has expanded considerably.
by Dr. William Chamberlin
On July 26, 2016, the United States Food and Drug Administration (FDA) issued a warning regarding the use of antibiotics in the fluoroquinolone class. These include levofloxacin (Levaquin), ciprofloxacin (Cipro), ciprofloxacin extended-release tablets, moxifloxacin (Avelox), ofloxacin and gemifloxacin (Factive).
Two of these drugs (levofloxacin and ciprofloxacin) are sometimes prescribed to treat Crohn’s disease via a pathogen model (AMAT). However, the risks associated with the fluoroquinolone class of medications are serious. Because of this, I will no longer recommend the use of levofloxacin or ciprofloxacin for the treatment of Crohn’s disease, except in extreme cases where the benefits may outweigh the serious risks.
Mercaptopurine, also known as 6-mercaptopurine or most commonly called 6-MP, is a generic medication used for the treatment for Crohn’s disease which is sold under the brand name Purinethol. Azathioprine (brand name Imuran) is a precursor of 6-MP which is converted to 6-MP by the liver.
Read the full article for more information on 6-MP and Azathioprine, including the history of development, how they are used in Crohn’s disease, the mechanism of action, the side effects, and the potential affect on Mycobacterium avium spp. paratuberculosis (MAP).